MS: Alkermes bags US$50m milestone from Biogen
Alkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes’ relapsing-remitting multiple sclerosis candidate diroximel fumarate (BIIB098).